ArticleOxford medical case reports2025
Methylene blue-induced Hemolysis in a patient with lidocaine-induced Methemoglobinemia: a case report.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethemoglobinemia is an uncommon but potentially life-threatening disorder where hemoglobin iron is oxidized to the ferric state, impairing oxygen transport. Topical anesthetics such as lidocaine can induce methemoglobinemia. Methylene blue (MB) is the first-line antidote, but high doses can oxidize hemoglobin and may precipitate hemolysis even in individuals with normal glucose-6-phosphate dehydrogenase (G6PD) activity. CASE PRESENTATION: A 31-year-old woman with recurrent genital herpes self-applied excessive 5% lidocaine cream (≈3 tubes/day) for two weeks. She presented with progressive fatigue, cyanosis and hypoxemia. Arterial blood gas showed methemoglobin 13.6%. She received intravenous MB at another hospital and subsequently developed severe anemia (hemoglobin 6.6 g/dL) with laboratory evidence of intravascular hemolysis. G6PD activity was normal. Supportive management included high-flow oxygen, oral ascorbic acid, intravenous antivirals and antibiotics, and transfusion of two units of packed red blood cells. Methemoglobin levels and hemoglobin gradually normalized, and she was discharged in stable condition.
conclusionThis case illustrates the paradoxical risk of MB-induced hemolysis in a G6PD-sufficient patient. Clinicians should consider alternative treatments such as ascorbic acid when managing methemoglobinemia and educate the public on safe use of topical anesthetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.